BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 15853868)

  • 1. Effectiveness and safety of eprosartan on pulse pressure for the treatment of hypertensive patients.
    Robles NR; Martín-Agueda B; López-Muñoz F; Alamo C;
    Int J Clin Pract; 2005 Apr; 59(4):478-84. PubMed ID: 15853868
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effectiveness of eprosartan in diabetic hypertensive patients.
    Robles NR; Martín-Agueda B; López-Muñoz F; Alamo C;
    Eur J Intern Med; 2008 Jan; 19(1):27-31. PubMed ID: 18206598
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Eprosartan provides safe and effective long-term maintenance of blood pressure control in patients with mild to moderate essential hypertension.
    Levine B
    Curr Med Res Opin; 2001; 17(1):8-17. PubMed ID: 11464450
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effect of treatment with eprosartan on pulse pressure: factors predicting response.
    de la Sierra A; Muñoz A; Arcos E; López JS; Relats J;
    Can J Cardiol; 2004 Oct; 20 Suppl C():17C-22C. PubMed ID: 16807619
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Eprosartan mesylate effectively reduces systolic and diastolic blood pressure in a Canadian primary care setting.
    Conter HS; McKay DW; Reiz RJ
    Can J Cardiol; 2004 Oct; 20 Suppl C():6C-10C. PubMed ID: 16807617
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The angiotensin receptor blocker eprosartan mesylate reduces pulse pressure in isolated systolic hypertension.
    Teitelbaum I; Chilvers M; Reiz RJ
    Can J Cardiol; 2004 Oct; 20 Suppl C():11C-16C. PubMed ID: 16807618
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Once-daily eprosartan mesylate in the treatment of elderly patients with isolated systolic hypertension: data from a 13-week double-blind, placebo-controlled, parallel, multicenter study.
    Punzi HA; Punzi CF
    J Hum Hypertens; 2004 Sep; 18(9):655-61. PubMed ID: 15042114
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of hypertension therapy based on eprosartan on systolic arterial blood pressure and cognitive function: primary results of the Observational Study on Cognitive function And Systolic Blood Pressure Reduction open-label study.
    Hanon O; Berrou JP; Negre-Pages L; Goch JH; Nádházi Z; Petrella R; Sedefdjian A; Sévenier F; Shlyakhto EV; Pathak A
    J Hypertens; 2008 Aug; 26(8):1642-50. PubMed ID: 18622244
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Atenolol and eprosartan: differential effects on central blood pressure and aortic pulse wave velocity.
    Dhakam Z; McEniery CM; Yasmin ; Cockcroft JR; Brown MJ; Wilkinson IB
    Am J Hypertens; 2006 Feb; 19(2):214-9. PubMed ID: 16448896
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of eprosartan on cytoplasmic free calcium mobilization, platelet activation, and microparticle formation in hypertension.
    Labiós M; Martínez M; Gabriel F; Guiral V; Munoz A; Aznar J
    Am J Hypertens; 2004 Sep; 17(9):757-63. PubMed ID: 15363816
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of eprosartan in combination with HCTZ in patients with essential hypertension.
    Sachse A; Verboom CN; Jäger B
    J Hum Hypertens; 2002 Mar; 16(3):169-76. PubMed ID: 11896506
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Eprosartan-based hypertension therapy, systolic arterial blood pressure and cognitive function: analysis of Middle East data from the OSCAR study.
    Radaideh GA; Choueiry P; Ismail A; Eid E; Berrou JP; Sedefdjian A; Sévenier F; Pathak A
    Vasc Health Risk Manag; 2011; 7():491-5. PubMed ID: 21915165
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Stress-associated hypertension in the work place: results of the STARLET project].
    Lüders S; Hammersen F; Kulschewski A; Frerichs A; Frieg R; Hahnheiser D; Reich G; Schnieders M; Schrandt G; Schrader J
    Dtsch Med Wochenschr; 2006 Nov; 131(46):2580-5. PubMed ID: 17096303
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of eprosartan on diastolic function and neurohormones in patients with hypertension and diastolic dysfunction.
    Voors AA; van de Wal RM; Hartog JW; Vijn RG; Hummel YM; Plokker TW; van Veldhuisen DJ; Jaarsma W
    Cardiovasc Drugs Ther; 2010 Feb; 24(1):33-40. PubMed ID: 20229056
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Superoxide dismutase and catalase anti-oxidant activity in leucocyte lysates from hypertensive patients: effects of eprosartan treatment.
    Labiós M; Martínez M; Gabriel F; Guiral V; Dasi F; Beltrán B; Muñoz A
    J Renin Angiotensin Aldosterone Syst; 2009 Mar; 10(1):24-30. PubMed ID: 19286755
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pulse pressure and risk of cardiovascular outcomes in patients with hypertension and coronary artery disease: an INternational VErapamil SR-trandolapril STudy (INVEST) analysis.
    Bangalore S; Messerli FH; Franklin SS; Mancia G; Champion A; Pepine CJ
    Eur Heart J; 2009 Jun; 30(11):1395-401. PubMed ID: 19351690
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Results of a phase III, 8-week, multicenter, prospective, randomized, double-blind, parallel-group clinical trial to assess the effects of amlodipine camsylate versus amlodipine besylate in Korean adults with mild to moderate hypertension.
    Kim SH; Kim YD; Lim DS; Yoon MH; Ahn YK; On YK; Lee JW; Kim IJ; Park JB; Kim JJ; Chung WS; Yang JY; Seo HS; Shin EK; Kim HS;
    Clin Ther; 2007 Sep; 29(9):1924-36. PubMed ID: 18035192
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Observational Study on Cognitive function And systolic blood pressure Reduction (OSCAR): preliminary analysis of 6-month data from > 10,000 patients and review of the literature.
    Shlyakhto E
    Curr Med Res Opin; 2007 Nov; 23 Suppl 5():S13-8. PubMed ID: 18093409
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Unique dual mechanism of action of eprosartan: effects on systolic blood pressure, pulse pressure, risk of stroke and cognitive decline.
    Ram CV; Rudmann MA
    Expert Rev Cardiovasc Ther; 2007 Nov; 5(6):1003-11. PubMed ID: 18035916
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A 26-week, prospective, open-label, uncontrolled, multicenter study to evaluate the effect of an escalating-dose regimen of trandolapril on change in blood pressure in treatment-naive and concurrently treated adult hypertensive subjects (TRAIL).
    Tytus RH; Burgess ED; Assouline L; Vanjaka A
    Clin Ther; 2007 Feb; 29(2):305-15. PubMed ID: 17472822
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.